Gatipotuzumab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes. Gatipotuzumab is being developed by Glycotope GMBH and is undergoing a phase II clinical trial for ovarian cancer.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:fdaUniiCode |
|
dbo:wikiPageExternalLink | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink | |
dbp:atcPrefix |
|
dbp:casNumber |
|
dbp:chemspiderid |
|
dbp:mabType |
|
dbp:source |
|
dbp:synonyms |
|
dbp:target |
|
dbp:type |
|
dbp:unii |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
rdf:type | |
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |